Neonatal sepsis (NS), a common disorder for humans, is recognized as a leading global public health challenge. This meta-analysis was performed to assess the accuracy of the serum amyloid A (SAA) test for diagnosing NS. The studies that evaluated the SAA test as a diagnostic marker were searched in Pubmed, EMBASE, the Cochrane Library, and Google Network between January 1996 and June 2013. A total of nine studies including 823 neonates were included in our meta-analysis. Quality of each study was evaluated by the quality assessment of diagnostic accuracy studies tool (QUADAS). The SAA test showed moderate accuracy in the diagnosis of NS both at the first suspicion of sepsis and 8-96 h after the sepsis onset, both with Q* = 0.91, which is similar to the PCT and CRP tests for the diagnosis of NS in the same period. Heterogeneity between studies was also explained by cut-off point, SAA assay, and age of included neonates. On the basis of our meta-analysis, therefore, SAA could be promising and meaningful in the diagnosis of NS.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3747616 | PMC |
http://dx.doi.org/10.1155/2013/520294 | DOI Listing |
Talanta
January 2025
State Key Laboratory of Materials for Integrated Circuits, Shanghai Institute of Microsystem and Information Technology, Chinese Academy of Sciences, Shanghai, 200050, China.
Research on metasurface sensors with high sensitivity, strong specificity, good biocompatibility and strong integration is the key to promote the application of terahertz waves in the field of biomedical detection. However, traditional metallic terahertz metasurfaces have shortcomings such as poor biocompatibility and large ohmic loss in the terahertz frequency band, impeding their further application and integration in the field of biosensing detection. Here, we overcome this challenge by proposing a high-performance terahertz metasurface based on gold nanoparticles and single-walled carbon nanotubes composite film.
View Article and Find Full Text PDFBackground: SAAs represent a promising biomarker of Lewy Body disease (LBD), with high sensitivity (87.3%, 95%CI: 0.755-0.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Wisconsin Alzheimer's Disease Research Center, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.
Background: The high prevalence of mixed-pathology dementias suggests that multi-drug treatments may improve clinical outcomes; thus, in-vivo biomarkers for co-pathologies are needed. We investigated a novel assay for detecting seeds of misfolded alpha synuclein (αSyn) and explored its relationship to outcomes including Alzheimer's disease (AD) biomarkers, clinical features, and cognitive trajectories, in two community-based cohorts enriched for AD risk.
Method: Cerebrospinal fluid (CSF) obtained from participants in the Wisconsin Registry for Alzheimer's Prevention and the Wisconsin Alzheimer's Disease Research Center (N=418 participants; 515 LPs; Table 1) was assayed using a clinically validated, qualitative Syn seed amplification assay (SAA; Amprion).
Alzheimers Dement
December 2024
Clinical Memory Research Unit, Department of Clinical Sciences Malmö, Faculty of Medicine, Lund University, Lund, Sweden.
Background: Identification of concomitant Lewy Body (LB) pathology might be important for the diagnostic and prognostic work-up of Alzheimer's disease (AD) in clinical practice and trials. Here, we aimed to determine whether the presence of LB pathology exacerbates AD-related disease progression.
Methods: Cognitively impaired (Mild Cognitive Impairment [MCI] and dementia, n=795) individuals from the ADNI cohort with available CSF α-synuclein amplification assay (SAA) and CSF p-tau/Aβ measures were included.
Alzheimers Dement
December 2024
School of Pharmacy, Chapman University, Irvine, CA, USA.
Background: Although novel treatments for Alzheimer's disease (AD) have begun to show modest therapeutic effects, agents that target hallmark AD pathology and offer neuroprotection are desired. Erythropoietin (EPO) is a glycoprotein hormone with neuroprotective effects but is faced with challenges including limited brain uptake and increased hematopoietic side effects with long-term dosing. Therefore, EPO has been modified and bound to a chimeric transferrin receptor monoclonal antibody (cTfRMAb); the latter shuttles EPO past the blood-brain barrier (BBB) into brain parenchyma and reduces its plasma exposure and potential for side effects.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!